CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.

Trial Details

NCT ID
NCT05257590
Phase
PHASE2
Sponsor
TaiRx, Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Nivolumab Injection [Opdivo]
  • CVM-1118
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Keelung, Taiwan|25.13089,121.74094
  • Tainan, Taiwan|22.99259,120.20507
  • Taipei, Taiwan|25.05306,121.52639
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Age 18+ (20+ for subjects in Taiwan)
  • Diagnosis of hepatocellular carcinoma
  • Pathologically or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) c…
  • Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed fro…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →